N
Neurocrine Biosciences
Neurology and Endocrinology Research and Therapy | Neurocrine Biosciences
About Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company that focuses on the discovery and development of treatments for neurological and endocrine-related diseases and disorders. The company has a portfolio of products and clinical programs that address a range of conditions, including tardive dyskinesia, Parkinson's disease, and endometriosis.
One of the company's key products is INGREZZA® (valbenazine), which is a prescription medicine used to treat adults with tardive dyskinesia. The company also has a pipeline of other drug candidates in various stages of clinical development for other neurological and endocrine-related conditions.
Neurocrine Biosciences' business model is based on the development and commercialization of its products. The company generates revenue from the sale of its approved drugs and may also receive milestone payments and royalties from its collaboration partners.
The company's target market includes patients with neurological and endocrine-related diseases and disorders, as well as the healthcare professionals who treat them. Neurocrine Biosciences operates in a competitive market, with a number of other companies developing and marketing treatments for similar conditions.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1992
- Headquarters
- San Diego, United States
- Listing
- IPO 1996
- Employees
- 2,134
- Open positions
- 120
- Dealroom signal
- 87.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, Verified Thoroughbreds
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 5 companies, latest May 2026
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | May 2026 | $1B | — | JPMorgan Chase & Co | ↗ |
| POST IPO EQUITY✓Other financing | Dec 2009 | $10M | — | Venrock | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Neurocrine Biosciences is 31K monthly website visits, up 24% over the last three months. Neurocrine Biosciences's team grew 2.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Soleno TherapeuticsRedwood City, United StatesDevelops and commercializes novel therapeutics for rare genetic disorders, with a lead FDA-approved treatment for hyperphagia in patients with Prader-Willi syndrome
$2.9Bvaluation
Voyager TherapeuticsCambridge, United StatesGene therapies for neurological diseases crossing blood-brain barrier.
$94Mvaluation
DiurnalCardiff, United KingdomSpecialty pharmaceutical developing hormone therapeutics for endocrine diseases
$36Mvaluation
Xenon PharmaceuticalsBurnaby, CanadaFrom families to genes, from genes to drugs.
$2.6Bvaluation
Nxera Pharma UK | Heptares TherapeuticsGreat Abington, United KingdomDevelops novel, small-molecule drugs for G-protein-coupled receptors
$400Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Avalon Ventures
Kleiner Perkins- SASchroder Ventures Life Sciences Advisers
Series B and later2 investors entered at this stage
Venrock
JPMorgan Chase & Co
Other known investors1 additional known investor
International Biotechnology Trust
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neurocrine Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neurocrine Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.